Jul 1, 2026 06:58AM

Jun 30, 2026 11:00AM

Jun 30, 2026 08:30AM

Jun 30, 2026 08:30AM

Jun 3, 2026 08:30AM

May 6, 2026 04:05PM

Mar 25, 2026 08:05AM Sarepta shares early clinical data from siRNA treatments for rare diseases

Mar 25, 2026 08:05AM

Mar 19, 2026 11:11AM

Mar 19, 2026 10:57AM

Mar 19, 2026 08:30AM

Mar 19, 2026 08:30AM

Mar 16, 2026 08:34AM

Mar 16, 2026 08:33AM Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duch

Mar 12, 2026 05:06PM

Mar 9, 2026 03:22PM

Mar 3, 2026 12:00PM

Feb 25, 2026 04:05PM

Feb 24, 2026 09:08AM

Feb 24, 2026 09:07AM

Jan 26, 2026 08:01AM Sarepta reports positive three-year results for Duchenne gene therapy

Jan 26, 2026 08:00AM

Jan 12, 2026 11:59AM

Jan 12, 2026 11:58AM

Jan 12, 2026 09:30AM

Dec 9, 2025 06:50AM

Nov 25, 2025 08:58AM

Nov 25, 2025 08:57AM Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025 07:31AM

Nov 24, 2025 07:30AM

Nov 20, 2025 03:59AM

Nov 14, 2025 02:59PM

Nov 14, 2025 02:54PM

Nov 14, 2025 02:02PM

Nov 3, 2025 04:13PM Sarepta completes confirmatory study for duchenne therapies, study misses primary endpoint

Nov 3, 2025 04:05PM

Oct 3, 2025 08:30AM

Aug 13, 2025 04:13PM

Aug 13, 2025 04:12PM

Aug 12, 2025 01:25PM

Aug 11, 2025 01:59PM

Aug 6, 2025 04:05PM Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

Aug 5, 2025 06:28PM

Jul 30, 2025 08:07AM

Jul 30, 2025 06:40AM

Jul 29, 2025 10:27AM

Jul 29, 2025 10:05AM

Jul 29, 2025 09:37AM

Jul 29, 2025 08:41AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Jul 29, 2025 07:22AM

325,585 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All